What is MOTS-C? What it does, benefits and what the evidence shows

MOTS-C is a 16-amino-acid peptide encoded inside mitochondrial DNA rather than the regular nuclear genome, first reported in 2015 by researchers at USC's Leonard Davis School of Gerontology. It isn't an approved drug, and the only controlled human trial we found of a MOTS-C-derived drug used a modified analog, CB4211, in a company-run Phase 1a/1b study. What exists is a substantial body of mouse research showing it regulates metabolism and improves exercise capacity when injected, plus a smaller set of human studies that only measured the peptide's natural levels in blood and muscle — not what happens when you inject more of it. That gap between the animal data and the human data is the single most important thing to understand before reading a benefits list for this compound.

What MOTS-C is and how it works

Most of what we think of as "genes" sit in the cell nucleus, but mitochondria carry their own small, separate genome, and MOTS-C comes from a short reading frame inside the mitochondrial 12S rRNA gene — hence the name, "mitochondrial open reading frame of the 12S rRNA-c." It's one of a small family of mitochondrial-derived peptides that also includes humanin. The peptide was first characterized in a 2015 paper in Cell Metabolism, which reported that MOTS-C "regulates insulin sensitivity and metabolic homeostasis," acting primarily on skeletal muscle (Lee et al., 2015, Cell Metabolism).

Mechanistically, MOTS-C inhibits the folate cycle and the purine synthesis pathway tied to it, which causes a metabolite called AICAR to build up inside the cell. AICAR is a well-known activator of AMPK, the enzyme that acts as a cell's fuel gauge and switches on fat-burning and glucose uptake when energy is low — the same pathway targeted by the diabetes drug metformin and mimicked by the "exercise pill" compound AICAR itself (Lee et al., 2015). Under metabolic stress, MOTS-C also translocates into the cell nucleus, where it appears to help regulate the expression of genes involved in the body's antioxidant stress response (Wan et al., 2023, Journal of Translational Medicine). Put simply: it's a signal your mitochondria send to the rest of the cell, and increasingly, to other tissues, when the body is under metabolic or physical stress — which is exactly when it naturally rises. No pharmaceutical company markets an approved MOTS-C product; everything about it beyond basic biology comes from academic research.

Worth noting for context: your body already makes MOTS-C without any supplementation. It circulates at measurable levels in blood, rises after exercise, and appears to decline with age in some study cohorts, though not consistently across every population studied (Zheng et al., 2023, Frontiers in Endocrinology). What's sold on the grey market is a synthetic version meant to supplement or exceed what your mitochondria are already producing on their own — the open question, covered below, is whether adding more from outside does in a person what it does in a mouse.

What people use it for

What the research actually shows

Metabolism and insulin sensitivity: consistently positive, but only in mice

The founding 2015 study injected MOTS-C into mice and found it prevented both age-dependent and high-fat-diet-induced insulin resistance, and prevented diet-induced obesity, without the injections themselves appearing to harm the animals (Lee et al., 2015, Cell Metabolism). A follow-up study built on this using a metabolomics approach in diet-induced obese mice: MOTS-C treatment (delivered by injection over three days) lowered blood glucose and shifted several metabolic pathways linked to insulin resistance, including sphingolipid and dicarboxylate metabolism (Kim et al., 2019, Physiological Reports). Both of these are legitimate, peer-reviewed, mechanistically detailed studies — and both are exclusively in mice, using injected peptide at controlled research doses, which tells you nothing directly about outcomes in a person.

Exercise capacity and healthy aging: the strongest mouse data, still only mice

The most-cited MOTS-C paper is a 2021 study in Nature Communications that tested the peptide across the mouse lifespan — in young (2-month), middle-aged (12-month) and old (22-month) mice. MOTS-C significantly enhanced physical performance at every age tested, and treatment started late in life (23.5 months, elderly for a lab mouse) still increased physical capacity and healthspan when given on an intermittent schedule (Reynolds et al., 2021, Nature Communications). This is a well-designed, rigorous animal study — multiple age groups, a late-life intervention arm, gene-expression analysis showing effects on both mitochondrial and nuclear genes — and it's the paper most responsible for MOTS-C's reputation as an "exercise mimetic." It remains, unambiguously, a mouse study.

What the human data actually measured

The same 2021 paper does include a human component, and it's worth being precise about what it shows: the researchers report that exercise induces endogenous MOTS-C expression in human skeletal muscle and circulation (Reynolds et al., 2021). In other words, when people exercise, their own bodies make more MOTS-C — a real and interesting finding, but it's an observation about a natural biological response, not a trial of injecting synthetic MOTS-C into anyone. A separate 2021 secondary analysis of a randomized trial compared 16 weeks of aerobic and resistance exercise with usual care in 49 breast cancer survivors (25 Hispanic, 24 non-Hispanic white) and measured their plasma MOTS-C. Levels rose significantly after exercise in non-Hispanic white participants but not in Hispanic participants, using an in-house lab assay (Dieli-Conwright et al., 2021, Scientific Reports). Again: exercise measured, blood levels measured, nothing administered. A comprehensive 2023 review in Frontiers in Endocrinology states this limitation directly, noting that "no effective method of applying MOTS-C in the clinic has been developed" and that human evidence is largely limited to observing how natural circulating MOTS-C changes with age and exercise, sometimes inconsistently across cohorts (Zheng et al., 2023, Frontiers in Endocrinology). As of today, we found no published controlled human trial of MOTS-C itself. The nearest thing is CohBar's randomized, placebo-controlled Phase 1a/1b trial (88 participants, NCT03998514) of CB4211, a modified analog of MOTS-C; the company's announcement reported no serious adverse events, with injection-site reactions the main side effect. That is a different molecule, and results were announced by the company rather than as data on MOTS-C itself.

Inflammation and cellular stress response

MOTS-C's translocation to the nucleus and its interaction with the antioxidant response pathway is well described mechanistically in cell and mouse models, and reviewers frame it as a plausible reason the peptide might have anti-inflammatory effects (Wan et al., 2023, Journal of Translational Medicine). That mechanistic plausibility hasn't yet been tested as an inflammation outcome in any human trial either.

Side effects and risks

Because no controlled human trial of MOTS-C itself has been published, there is no published human safety data for injecting it: no dose-ranging study, no adverse-event data, no pharmacokinetic data in a person, and no data on longer-term use. The only related human data, from the analog trial above, come from a different molecule. That's simply an unknown, not a reassurance. The mouse studies report no obvious toxicity at the doses and durations tested, but toxicology findings in mice don't reliably predict what happens in humans, and none of the published mouse work was designed as a formal safety study in the way a Phase 1 human trial would be. The most direct account of clinical translation efforts, a 2023 review, states that "no effective method of applying MOTS-C in the clinic has been developed" — meaning the researchers who study it most closely don't consider it clinic-ready either (Zheng et al., 2023).

On top of the missing human safety data, everything sold as MOTS-C on the grey market is unregulated and for research use only, with none of the manufacturing oversight or identity confirmation an approved drug would get. Our own data shows what that looks like in practice: solid purity, but a real and fairly consistent overfill pattern (below), which is a manufacturing-and-labeling issue distinct from the open question of whether the peptide itself does anything useful or safe in a person.

The regulatory picture may shift. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding MOTS-C, along with BPC-157, KPV, TB-500, Epitalon and Semax, to the 503A bulks list that licensed compounding pharmacies can draw on. The vote is non-binding: the Secretary of Health and Human Services still has to approve any addition, and pharmacies can't compound it until the final rule is in place (NCPA, July 31, 2026). Even if it goes through, that would allow a prescription, pharmacy-compounded product; it would not mean FDA has found MOTS-C safe or effective.

What the lab tests show

As of September 30, 2026, our database includes 22 MOTS-C vials from 9 vendors, drawn from 15 lab reports dated April 2025 through July 2026. As of September 29, 2026, purity was consistently strong: all 22 tested vials had a purity result, 17 of them (77%) came in at 99% or higher, and none tested under 95% — the median purity was 99.34%. Dose against label ran a median of +13.5% over label, meaningfully higher than compounds like tirzepatide or semaglutide, though only 4 of the 22 vials landed within ±5% of label and 6 within ±10%. None of the 22 vials measured more than 20% under or over label, and none failed outright under our definition (empty, under 95% purity, more than 20% under label, or more than 50% over) — a clean record on failures specifically, even with the overfill pattern.

This is still a small sample by our standards — 9 vendors and 22 vials as of September 29, 2026 is enough to see a pattern, not enough for it to be the last word, and a single vendor's results can move these numbers more than they would for a heavily tested compound. Here's how the ranked vendors for MOTS-C look right now, based on lab reports buyers have actually submitted — this updates as new reports come in and may be short if too few vendors have five or more reports yet:

Ranked isn't automatically good, and the table flags any vendor whose failed-vial rate on file runs above 5%. For the live, continuously updated numbers, see the MOTS-C results page.

Buying smarter

Given that MOTS-C's overfill pattern in our data runs higher than average, it's worth ordering a quantity test specifically rather than assuming your vial matches its label — that's a manufacturing and labeling check, separate from and easier to verify than anything about the peptide's biological effects. Check the vendor's specific MOTS-C record on the MOTS-C results page rather than their overall reputation, since a vendor's numbers on a different compound don't tell you much about how they source or store this one. How to get a peptide tested covers ordering independent identity, purity and quantity testing from a lab. If a report comes back with a purity fail or a large deviation from label, stop using that batch, tell anyone else who bought from the same run, bring the report to the vendor, and submit it to VendorVerify so it's part of the record for the next buyer checking that vendor.

Database figures without a date update automatically from VendorVerify's lab results; dated figures are snapshots. MOTS-C is sold research-use-only and has not been tested in any published controlled human trial for the uses discussed above. This isn't medical advice.